New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
06:37 EDTMNKDMannKind downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray downgraded MannKind to Underweight as it sees only a 20% chance of a "cleanly" positive FDA panel vote on Afrezza. Piper sees a "number of obstacles" in the briefing documents and lowered its price target for the stock to $1.50 from $5.
News For MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
11:47 EDTMNKDMannKind's Afrezza lags behind in inhaled insulin market, The Street reports
The number of prescriptions written for MannKind's (MNKD) Afrezza is lagging behind in the diabetes market, reports The Street. This comes five months after Sanofi (SNY) launched the product. Afrezza is also under-performing Exubera, the first inhaled insulin launched by Pfizer (PFE) nine years ago. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use